Avalo Therapeutics, Inc.
AVTX$318M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWAYNE23 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AVTX News
Catalyst Timeline
0 upcoming, 2 past
No catalysts found.
Drug Pipeline
FP01
Chronic Refractory Cough
AVTX-002
Non-Eosinophilic Asthma
CERC-301
Major Depressive Disorder
AVTX-009 Regimen 1
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FP01 | Phase 2 | Chronic Refractory Cough | - | - |
AVTX-002 | Phase 2 | Non-Eosinophilic Asthma | - | - |
CERC-301 | Phase 2 | Major Depressive Disorder | - | - |
AVTX-009 Regimen 1 | Phase 2 | Hidradenitis Suppurativa | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply